Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, 270 Dong-An Rd, Shanghai, 200032, China.
Institute of Thoracic Oncology, Fudan University, Shanghai, 200032, China.
J Cancer Res Clin Oncol. 2020 Jun;146(6):1603-1613. doi: 10.1007/s00432-020-03180-3. Epub 2020 Mar 12.
Previous studies have reported similar survival between segmentectomy and lobectomy for patients with small-sized non-small cell lung cancer. However, part of those patients were with adenocarcinoma in situ or minimally invasive adenocarcinoma, which were considered to have a favorable prognosis. We compared survival outcomes of patients with clinical N0 invasive lung adenocarcinomas of no more than 2 cm who underwent segmentectomy or lobectomy.
Between June 1, 2008, and May 31, 2018, 1018 patients with clinical N0 invasive lung adenocarcinomas of no more than 2 cm in diameter on thin-section chest CT scans were retrospectively included in this study. Of them, 214 underwent segmentectomy and 804 underwent lobectomy. Propensity-score matching of preoperative factors, such as gender, age, smoking status, forced expiratory volume in 1 s predicted%, tumor's CT appearance, tumor size on CT scan and tumor location was used to compare survival outcomes of those patients receiving different surgical treatments. Cox proportional hazard regression model was used to identify independent prognostic factors. This study was approved by the Committee for Ethical Review of Research (Fudan University Shanghai Cancer Center IRB# 090977-1). Informed consent was waived because of the retrospective nature of this study.
Average follow-up time was 42.5 months. Before matching, the lobectomy group had a shorter recurrence-free survival (P = 0.02), but similar overall survival (P = 0.60). After matching, no significant difference of overall survival or recurrence-free survival was found between the two groups (P = 0.70 and P = 0.40, respectively).
Our results suggest that segmentectomy achieved similar recurrence-free and overall survival compared with lobectomy for patients with clinical N0 invasive lung adenocarcinomas of no more than 2 cm. Therefore, segmentectomy could be an alternative approach. These results need to be further validated by randomized trials.
先前的研究报告显示,对于患有小尺寸非小细胞肺癌的患者, 肺段切除术和肺叶切除术的生存情况相似。然而,其中部分患者为原位腺癌或微浸润性腺癌,这些患者的预后被认为较好。我们比较了临床 N0 期直径不超过 2cm 的浸润性肺腺癌患者接受肺段切除术或肺叶切除术的生存结果。
回顾性纳入 2008 年 6 月 1 日至 2018 年 5 月 31 日期间在薄层胸部 CT 扫描上直径不超过 2cm 的临床 N0 期浸润性肺腺癌患者 1018 例。其中 214 例行肺段切除术,804 例行肺叶切除术。通过术前因素的倾向性评分匹配,如性别、年龄、吸烟状态、1 秒用力呼气量预计值%、肿瘤 CT 表现、CT 扫描上肿瘤大小和肿瘤位置,比较接受不同手术治疗的患者的生存结果。采用 Cox 比例风险回归模型确定独立的预后因素。本研究经复旦大学附属肿瘤医院伦理审查委员会批准(IRB#090977-1)。由于本研究为回顾性研究,故豁免了患者知情同意。
平均随访时间为 42.5 个月。在匹配前,肺叶切除术组的无复发生存率较低(P=0.02),但总体生存率相似(P=0.60)。在匹配后,两组的总体生存率或无复发生存率无显著差异(P=0.70 和 P=0.40)。
我们的研究结果表明,对于临床 N0 期直径不超过 2cm 的浸润性肺腺癌患者,肺段切除术与肺叶切除术的无复发生存率和总体生存率相当。因此,肺段切除术可以作为一种替代方法。这些结果需要通过随机试验进一步验证。